Table 2.
Characteristics of RSV-positive subjects
| # | Sex | Age, years | Sample date | RSV | Co-detections (Ct) | |
|---|---|---|---|---|---|---|
| Resp-4-Plex (Ct) | Allplex Respiratory Panel 1 (Ct) | |||||
| 1 | F | 42 | 13/12/2021 | POS (22.17) | RSV-B (24.79) | SP (27.42) |
| 2 | F | 86 | 16/12/2021 | POS (22.43) | RSV-A (28.25) | – |
| 3 | F | 71 | 16/12/2021 | POS (21.65) | RSV-B (23.68) | – |
| 4 | M | 70 | 19/12/2021 | POS (19.35) | RSV-A (22.56) | – |
| 5 | F | 29 | 20/12/2021 | POS (18.91) | RSV-A (25.55) | RV (39.09) |
| 6 | M | 47 | 20/12/2021 | POS (20.47) | RSV-A (23.38) | SP (27.96) |
| 7 | F | 52 | 20/12/2021 | POS (21.09) | RSV-A (24.94) | SARS-CoV-2 (26.86); HI (38.33) |
| 8 | F | 30 | 26/12/2021 | POS (18.18) | RSV-A (22.66) | SARS-CoV-2 (23.81); RV (39.33) |
| 9 | M | 53 | 26/12/2021 | POS (37.31) | RSV-B (41.79) | SARS-CoV-2 (31.90) |
| 10 | F | 79 | 28/12/2021 | POS (21.39) | RSV-B (25.62) | – |
| 11 | F | 21 | 02/01/2022 | POS (25.88) | RSV-B (25.09) | CoV-229E (25.42); SP (32.94) |
| 12 | F | 21 | 02/01/2022 | POS (31.77) | RSV-B (33.39) | EV (33.75) |
| 13 | F | 50 | 02/01/2022 | POS (23.55) | RSV-B (26.16) | – |
| 14 | F | 72 | 03/01/2022 | POS (30.57) | RSV-B (33.94) | SARS-CoV-2 (26.47) |
| 15 | F | 49 | 03/01/2022 | POS (21.65) | RSV-A (29.30) | SP (35.11) |
| 16 | F | 39 | 09/01/2022 | POS (31.94) | RSV-B (35.31) | SARS-CoV-2 (32.29) |
| 17 | M | 83 | 23/01/2022 | POS (20.38) | RSV-B (23.13) | – |
| 18 | M | 91 | 23/02/2022 | POS (34.72) | RSV-A (38.17) | SARS-CoV-2 (30.51) |
| 19 | F | 91 | 23/02/2022 | POS (36.42) | NEG | SARS-CoV-2 (20.66) |
CoV-229E, coronavirus 229E; Ct, cycle threshold; EV, enterovirus; HI, Hemophilus influenzae; NA, not available; RV, rhinovirus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SP, Streptococcus pneumoniae